Highest-materiality recent filing
Zai Lab President & COO Josh Smiley departs; responsibilities absorbed by CEO
Josh Smiley ceases as President and COO effective May 18, 2026; last day is May 22, 2026.
Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR
Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M
Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).
Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M
Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.
Zai Lab secures RMB300M ($42.1M) revolving credit facility from Industrial Bank for working capital
Guarantee and credit line contract with Industrial Bank for up to RMB300M (~$42.1M) to Zai Lab Shanghai.
Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability
Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).
Zai Lab shareholders approve all 14 proposals at 2025 AGM
All director nominees re-elected, including Samantha Du, John Diekman, Richard Gaynor, Nisa Leung, William Lis, Scott Morrison, Leon Moulder, Michel Vounatsos, and Peter Wirth.
Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability
Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.
Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M
Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.
Zai Lab secures RMB300M ($41.1M) revolving credit facility from Bank of Communications
Guarantee and loan contract signed Jan 2, 2025 with BOCOM for working capital loans to subsidiary Zai Lab Shanghai.
Priced underwritten public offering of 7,843,137 ADSs at $25.50 per ADS; expected gross proceeds ~$200M.
Zai Lab updates risks: employee medical fraud probes in China, Optune patent setbacks
Several current/former employees in ZEJULA sales team under criminal investigation by Chinese authorities for alleged medical insurance fraud; individuals detained or under compulsory measures.
Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive
Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M
Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
Zai Lab secures RMB250M credit facility from China Merchants Bank for subsidiary working capital
Parent company issued guarantee to China Merchants Bank (Shanghai) for loans up to RMB250M (~$34.4M) for wholly owned subsidiary Zai Lab Shanghai.
Zai Lab shareholders approve 2024 equity plan, re-elect all directors at AGM
2024 Equity Incentive Plan approved (568.4M for, 215.2M against), replacing 2022 Plan with more shares.
Zai Lab CMO Dr. Harald Reinhart to retire; Dr. Rafael Amado to lead all Global R&D
Dr. Harald Reinhart, President, Head of Global Development (NSAiID), retiring effective June 30, 2024.
On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.
On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings